Closing the CGT Commercial Readiness Gap: Why Early Decisions Matter

Cell and gene therapy developers can achieve regulatory approval and still face operational friction that threatens commercial viability. While scientific breakthroughs and clinical efficacy drive early milestones, the ability to transition from clinical manufacturing to sustained, full-scale market delivery requires an entirely different operational foundation.

Unlike traditional biologics, scaling an advanced therapy — whether allogeneic or autologous, oncology or rare disease — exposes deep systemic dependencies. Facility capacity, quality systems, automated infrastructure, and validation strategies that support early-phase trials often break down under the demands of commercial volume and multi-site distribution.

These constraints rarely originate late in development. They stem from choices made years earlier, when early decisions prioritize immediate clinical speed without evaluating downstream impacts on facility design, technology transfer, data integrity, or quality oversight.

Commercial readiness must be built as a core development discipline, aligning Manufacturing, Quality, Regulatory, Engineering, IT, and CQV early to build a resilient, scalable operating model.

A manufacturing process optimized for Phase I/II clinical supply is rarely designed for commercial performance. However, early process choices dictate the cost, complexity, and technical feasibility of future scale-up or scale-out strategies. As programs advance toward pivotal trials and commercial license applications, operational systems must expand to accommodate higher throughput, expanded treatment networks, additional manufacturing suites, and multi-region technology transfers.

Each transition introduces significant technical, operational, and regulatory complexity:

Increasing output does not automatically create a scalable operating model.

For advanced therapies, growth places pressure on an interconnected network: collection and logistics, production, analytical testing, product release, supplier management, data systems, quality oversight, scheduling, and treatment-site coordination. A constraint in one area can undermine the performance of the whole system.

Additional manufacturing capacity offers limited benefit if analytical testing cannot support higher volume. New equipment expands production potential while qualification activities delay deployment. Additional sites extend geographic reach while introducing challenges in process transfer, comparability, data governance, and consistent quality oversight.

These are not isolated capacity issues. They are dependencies that determine whether the broader operating model can support growth. The critical question is not how much product an organization can make. It is whether every connected process can support the intended scale without compromising quality, control, or delivery.

Manufacturing scale-up exposes constraints well beyond floor space and bioreactor volume. Analytical testing capacity, release timelines, supply-chain reliability, technology transfer, and quality oversight directly govern the ability to deliver product consistently. Because a manufacturing line is ultimately only as fast as its slowest quality review or release assay, assessing scalability requires looking across the entire delivery network before demand forces the issue.

Commercialization depends on coordinated decisions across Manufacturing, Quality, Regulatory, Clinical, Engineering, IT, and CQV. Yet each function manages its own priorities, timelines, and deliverables, and the gaps between them grow when a decision in one area creates new requirements in another.

When these dependencies are identified early, teams plan for them. When they surface late, the result is duplicate work, competing priorities, added cost, and delay at critical milestones. The greatest readiness risks often sit between functions, not within them.

A manufacturing change triggers regulatory comparability considerations. A new technology stack introduces strict system assurance requirements. A facility layout choice bounds future qualification and process transfer options. When these decisions are made within functional silos, the gaps between them become launch risks.

True commercial readiness depends on integrated program planning rather than siloed tracking. This requires clear ownership over cross-functional dependencies, routine governance focused on cross-discipline alignment, and early escalation of decisions that risk limiting future operating flexibility. Functional milestone performance alone is never a true proxy for operational readiness.

CQV delivers its greatest strategic value when it informs facility, equipment, automation, and system decisions before designs are final. When qualification and validation begin only after infrastructure and technology are selected, the chance to resolve risk through design may already be gone. Teams are then left to close avoidable gaps through remediation, added documentation, rework, or extended qualification timelines.

A risk-based approach aligned with ICH Q9(R1) and a lifecycle mindset consistent with ICH Q10 and ICH Q12 bring CQV, Engineering, Quality, IT, and project execution together earlier, so system requirements, risk assessments, and intended use are defined in step with the program.

The objective is not to maximize validation activity. It is to build facilities, systems, and processes that stay fit for purpose and under control as the program evolves.

Early CQV planning aligns facility and equipment design, system requirements, risk assessments, and qualification deliverables before decisions become difficult or costly to reverse. It improves visibility into readiness risks, reduces avoidable rework, and supports a more coordinated path from construction through qualification to operational readiness.

Quality operations must evolve at the same pace as manufacturing scale. Higher output places immediate pressure on change control, deviation management, investigation timelines, supplier oversight, and data governance. Expanding production without strengthening these core quality functions doesn't eliminate the bottleneck — it merely shifts it from manufacturing to quality release.

Growth brings increased process complexity, expanded facilities, new suppliers, and denser data flows. Organizations require mature processes to manage change, resolve deviations, and safeguard data integrity under 21 CFR Part 11 and EU Annex 11 expectations. Because commercial success requires both production capacity and operational control, bringing CQV and quality strategy into early scale-up planning is essential to building capacity and compliance in parallel.

Not every barrier to patient access can be solved by the developer. Pricing, reimbursement, treatment infrastructure, and healthcare delivery will continue to shape how broadly advanced therapies reach patients. But developers do control whether their own operating models add barriers to their own.

That means moving beyond milestone-based readiness reviews. Meeting a development milestone does not mean the organization is prepared for the demands of the next phase. At every major program transition, leadership should be able to answer three questions.

Most scale-up constraints are not discovered by any single function. They are found by looking across Manufacturing, Quality, Engineering, IT, and Validation at once — and that is where AVS works.

AVS Life Sciences helps cell and gene therapy developers:

Advancing cell and gene therapy depends on more than scientific breakthroughs and regulatory milestones. It depends on translating those breakthroughs into reliable, controlled, and sustainable delivery.

That outcome is shaped years before commercialization: by how processes are developed, how facilities and technologies are selected, how quality systems mature, and how functions coordinate as complexity increases.

Commercial readiness is not about building tomorrow's organization today. It is about avoiding decisions today that make tomorrow unnecessarily difficult. The most valuable moment to find a scale-up constraint is before it affects manufacturing performance, commercialization timelines, or the ability to deliver treatment.

The goal is not simply to get a therapy approved. It is to build the operational foundation required to deliver it.